Kidney Transplant Rejection Market is segmented By Treatment (Immunosuppressive Drugs, Antibody-mediated Rejection Therapies), By Rejection Type (Chro....
Market Size in USD
CAGR8.6%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.6% |
Market Concentration | Medium |
Major Players | Eledon Pharmaceuticals, Sangamo Therapeutics, AlloVir, CSL Behring, Hansa Biopharma |
The kidney transplant rejection market is estimated to be valued at USD 1.5 Bn in 2024 and is expected to reach USD 2.68 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031. Factors such as the increasing prevalence of renal diseases, rising geriatric population, and growing awareness about organ transplantation are fueling the demand for effective rejection treatments.